ADVFN - Advanced Financial Network.
HOME» NYSE » J » JNJ Stock Price » JNJ Stock News

Johnson & Johnson Share News

 Johnson & Johnson Stock Price
JNJ Stock Price
 Johnson & Johnson Stock Chart
JNJ Stock Chart
 Johnson & Johnson Stock News
JNJ Stock News
 Johnson & Johnson Company Information
JNJ Company Information
 Johnson & Johnson Stock Trades
JNJ Stock Trades

J&J CEO: Will Make Any Changes Needed After Recall

DOW JONES NEWSWIRES Johnson & Johnson's (JNJ) chief executive vowed to make whatever changes are needed for its manufacturing processes to meet consumers' expectations and the company's own standards, saying it has hired independent quality experts to help. The company recalled about 1,500 lots of bottled products last week, including pediatric versions of Tylenol, Motrin, Zyrtec and Benadryl. Its McNeil Consumer Healthcare unit said it was withdrawing the over-the-counter products, starting late last Friday, because of manufacturing problems at its Fort Washington, Pa., plant In an open letter Friday to all those who use J&J products on the firm's corporate blog, Chairman and Chief Executive Bill Weldon called the recalls a disappointment to him and the rest of the company and its workers. "I have been assured that the chance of a serious medical event from the recalled products is remote," he said. "Even so, this does not give us comfort; one of our companies has let you down." He reiterated that McNeil suspended manufacturing at the Pennsylvania plant and has hired independent quality experts to help the facility return to the proper standards and also reevaluate the systems and manufacturing processes across the organization. He ended the note by saying the company "will work hard to earn back your confidence." A House committee said earlier this week it is opening an investigation into conflicting accounts of what had prompted the recall, as well as how the company handled consumer complaints about foreign matter in the bottles. Johnson & Johnson shares were up 0.2% at $63.42 in after-hours trading. The stock is down modestly so far this year. Johnson & Johnson blog: -By Joan E. Solsman, Dow Jones Newswires; 212-416-2291;

Stock News for Johnson & Johnson (JNJ)
09/24/201410:41:48Correction to Inovio, GeneOne Headline
08/29/201417:08:09Health Care Down as Traders Bet on Growth Areas -- Health-Care...
08/29/201411:10:12J&J, Bayer Aim to Expand Xarelto's Uses
07/28/201423:33:30Wanted: Biotech Startups in New York City
07/28/201412:54:18Press Release: FDA expands approved use of Imbruvica for chronic...
07/22/201417:52:34Study Finds New Cancer Risk from Hysterectomy Device
07/22/201409:46:18U.S. Hot Stocks: Hot Stocks to Watch
07/15/201416:52:02MARKET SNAPSHOT: U.S. Stocks Swing As Yellen Speaks
07/15/201416:49:26MARKET SNAPSHOT: U.S. Stocks Open Higher; J.P. Morgan Rallies
07/13/201406:18:25MARKET SNAPSHOT: Tech, Bank Earnings To Test Economic Recovery
07/10/201416:34:09Doctor Quits Uterine-Device Safety Panel Over Conflict--Update
07/10/201413:57:14Doctor Quits Uterine Device Safety Panel Over Conflict
07/08/201417:50:39Energizer to Close Montreal Feminine-Care Products Site
07/07/201419:51:09CVS Halts Sales of Certain Cold Medicines in West Virginia Stores...
05/21/201416:18:35FDA Order on Surgical Device Divides Doctors
05/09/201420:38:21Use of Morcellators in Hysterectomy Gets Further Backing
05/06/201417:48:19European Physicians Study Risks of a Uterine Surgical Method
04/29/201412:44:46LONDON MARKETS: U.K. Stocks Advance, But Shire Loses Grip Of...
04/29/201410:31:31Allergan Contacts Possible Buyers, Including Sanofi, J&J -Bloomberg
04/24/201420:15:44Zimmer-Biomet: The Deal That Shook Warsaw, Ind. -- 6th Update

Johnson & Johnson and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations